Compare Incyte Corporation (INCY) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Financial Select Sector SPDR Fund — how do they compare? Incyte Corporation trades at $113.51 (market cap $22.85B), while Financial Select Sector SPDR Fund trades at $54.69 (market cap $50.06B). The key difference: Financial Select Sector SPDR Fund is far larger — about 2.2× Incyte Corporation's market cap, and Financial Select Sector SPDR Fund is more actively traded (47,464,120 versus 1,927,029). Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| INCY | XLF | |
|---|---|---|
Market Cap | $22.85B | $50.06B |
Volume | 1,927,029 | 47,464,120 |
Sector | Health | — |
52-Week High | $129.93 | $58.55 |
52-Week Low | $83.80 | $47.80 |
Typical Hold Time | 33 Days | 104 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
XLF trades at $54.71, up 1.78% with a bearish technical signal from moving averages. The ETF faces sector headwinds as financial stocks lag the S&P 500 by the widest margin since 1990 despite rising bank profits. Recent Fed stress test changes and interest rate hikes create both opportunities and volatility for financial sector holdings.
Financial sector exposure benefits from rising interest rates but faces regulatory uncertainty and market underperformance risks. The divided Congress outlook suggests limited major legislation, maintaining sector-specific policy focus. XLF's concentrated 76-holding portfolio offers large-cap financial exposure with competitive 0.08% expense ratio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
